Midostaurin and Mobocertinib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mobocertinib
Midostaurin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure
Interaction Deep Dive
Concomitant use of mobocertinib (CYP3A inhibitor) with a CYP3A substrate with a narrow therapeutic index should be avoided due to a decrease in substrate plasma concentrations, where minimal concentration changes may lead to serious therapeutic failures. Coadministration of mobocertinib with midazolam (a CYP3A substrate) decreased the AUC of midazolam by 32% and 16%, respectively1.
Why it happens (mechanism)
Induction of the metabolism of CYP3A substrates by mobocertinib
Literature reports
1 report — tap to read
a) Coadministration of mobocertinib 160 mg once daily with oral or IV midazolam (a CYP3A substrate) decreased the AUC of midazolam by 32% and 16%, respectively1.
Common questions
Can I take Midostaurin and Mobocertinib together?
Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Midostaurin and Mobocertinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Midostaurin or Mobocertinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: EXKIVITY(TM) oral capsules, mobocertinib oral capsules. Takeda Pharmaceuticals America Inc (per FDA), Lexington, MA, 2021.
Keep reading about Mobocertinib
Keep reading about Midostaurin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist